Analytical Data
-
Gene name
TRGC1
- Application
-
Alternative Names
TRGC1; T cell receptor gamma constant 1
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0CF51
-
Expression Region
D1-A138
-
Protein Length
Partial
-
Molecular Weight
30-40 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRGC1, or T-cell receptor gamma constant region 1, plays a significant role in the immune response and is primarily involved in the function of gamma delta (γδ) T cells, which are important for recognizing and responding to a wide range of pathogens and tumors. Research into TRGC1 recombinant proteins has gained traction due to their potential applications in immunotherapy and vaccine development. Understanding the structure and function of TRGC1 is crucial for elucidating its role in T-cell signaling and activation, as well as its interaction with other molecules in the immune system. Recombinant TRGC1 proteins can be used to study the mechanisms underpinning γδ T cell activation and proliferation, facilitating the identification of novel therapeutic targets for diseases such as cancer and infectious diseases. Advances in protein expression technologies allow for the production of biologically active TRGC1 protein, enabling researchers to investigate its immunological functions in vitro and in vivo. This research not only enhances our comprehension of T cell biology but also opens avenues for innovative treatments that harness the power of the immune system. Further studies on TRGC1 may lead to the development of more effective immune-based therapies, ultimately contributing to improved health outcomes.
